Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Buechler Kenneth FOwnership Type:Direct OwnershipSecurities:Non-Qualified Stock OptionNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-9,041Price:--
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Buechler Kenneth FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:9,041Price:$21.07
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Iskra Michael S.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Iskra Michael S.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,773Price:$47.94
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Iskra Michael S.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Busky Joseph MOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Busky Joseph MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,234Price:$47.94
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Busky Joseph MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Bujarski Robert JosephOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Bujarski Robert JosephOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,805Price:$47.94
Filings by filing date
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Buechler Kenneth FOwnership Type:Direct OwnershipSecurities:Non-Qualified Stock OptionNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-9,041Price:--
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Buechler Kenneth FOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:9,041Price:$21.07
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Iskra Michael S.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Iskra Michael S.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,773Price:$47.94
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Iskra Michael S.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Busky Joseph MOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Busky Joseph MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,234Price:$47.94
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Busky Joseph MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Bujarski Robert JosephOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,925Price:--
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Bujarski Robert JosephOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,805Price:$47.94
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9975 Summers Ridge Road SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.quidelortho.com |
IR: | See website |
Key People | ||
Robert Joseph Bujarski Interim President, Chief Operating Officer, Executive Vice President | Michael S. Iskra Interim Chief Executive Officer, Executive Vice President, Chief Commercial Officer | Joseph M. Busky Chief Financial Officer |
Michelle A. Hodges Senior Vice President, General Counsel | Werner E. Kroll Senior Vice President - R&D |
Business Overview |
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories. |
Financial Overview |
For the fiscal year ended 31 December 2023, Quidelortho Corp revenues decreased 8% to $3B. Net loss totaled $10.1M vs. income of $548.7M. Revenues reflect North America segment decrease of 26% to $1.88B. Net loss reflects Selling, General & Administrative Expens increase of 23% to $601.4M (expense), Term Loan increase from $74.5M to $178.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $9.66 to -$0.15. |
Employees: | 7,100 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4,949M as of Dec 31, 2023 |
Annual revenue (TTM): | $2,998M as of Dec 31, 2023 |
EBITDA (TTM): | $709.70M as of Dec 31, 2023 |
Net annual income (TTM): | -$10.10M as of Dec 31, 2023 |
Free cash flow (TTM): | $70.90M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $2,247M as of Dec 31, 2023 |
Shares outstanding: | 66,878,683 as of Mar 18, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |